<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">Comparative assessments of signals discussed at the Pharmacovigilance Risk Assessment Committee have suggested that reports of ADRs often supported signals, but that support from multiple sources of evidence increased the likelihood of regulatory action (e.g. changes to Summaries of Product Characteristics) [
 <xref ref-type="bibr" rid="CR8">8</xref>, 
 <xref ref-type="bibr" rid="CR9">9</xref>]. Similar investigations carried out in the USA have highlighted the same finding [
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR11">11</xref>]. Regulatory actions, however, appear to be inconsistent across international settings; discrepancies in communications of the same risks of drug-induced harms in healthcare systems have been recorded, and it has been suggested that they may be better understood by characterizing the strength of the underpinning evidence [
 <xref ref-type="bibr" rid="CR12">12</xref>, 
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
